08:11 EST Cardiol Therapeutics (CRDL) trading halted, news pending
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDL:
- Cardiol Therapeutics Reaches 50% Enrollment in Pivotal Phase III MAVERIC Trial for Recurrent Pericarditis
- Cardiol Therapeutics: Strong Buy Rating Backed by Promising CardiolRx Trial Results and Strategic Growth Potential
- New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
- Cardiol Therapeutics Reports Positive Phase II ARCHER Trial Results for CardiolRx™
- Cardiol Therapeutics Reports Financial Challenges Amid Clinical Progress